Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

Selected Publication:

Andersen, MH; Keikavoussi, P; Brocker, EB; Schuler-Thurner, B; Jonassen, M; Sondergaard, I; Straten, PT; Becker, JC; Kampgen, E.
Induction of systemic CTL responses in melanoma patients by dendritic cell vaccination: Cessation of CTL responses is associated with disease progression
INT J CANCER. 2001; 94(6): 820-824. Doi: 10.1002/ijc.1536
Web of Science FullText FullText_MUG

Leading authors Med Uni Graz: Becker Jürgen Christian
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: Two HLA-A2-positive patients with advanced stage IV melanoma were treated with monocyte-derived dendritic cells (DC) pulsed with either tumor peptide antigens from gp100, MART-1 and MAGE-3 alone or in combination with autologous oncolysates. Clinically, the rapid progression of disease was substantially stalled and both patients were alive for more than 15 months after initiation of therapy. Specific CTL reactivity against several tumor antigens was detectable in peripheral blood, which declined just before reactivation of disease progression. Furthermore, CD3 zeta -chain expression detected by Western blotting was decreased in PBL at this time. In summary, our data confirm that DC-based vaccinations induce peptide-specific T cells in the peripheral blood of advanced-stage melanoma patients. Although successful induction of systemic tumor antigen-specific CTL may not lead to objective clinical tumor regression, their presence are indicative of a prolonged survival. (C) 2001 Wiley-Liss, Inc.
Find related publications in this database (Keywords): tumor immunity; immunotherapy; dendritic cells; vaccination; T lymphocytes